Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

DiaMedica Therapeutics Inc.DMAC · healthcare
GradeNonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $61.4M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin datanot computable: distress, fortress balance sheet
Inputs computable4 of 14
Graded fromfilings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date
Last close$8.002026-10-08; market equity $431.4M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$6$8NovDecJanFebMarAprMayJunJulAugSepOct$8.01
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2019nonen/aQ2
Apr 21, 2020nonen/aQ1
Mar 21, 2021nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.

We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 25.7%[3-4]
Short runway. cash runway is 2.0 months[5]
Thin data. 4 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 54.3
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(6.9%)[1,6-8](6.6%)54.38112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 12.8
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-primenot computable(0.31)
one or more required annual facts are missing
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio11.81x[9-10]2.96x12.88392025-12-31
Growth and financing, sleeve percentile 43.0
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 1
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years21.3%[1,8,11-12]2.1%20.37042025-12-31
Net share issuance, one year25.7%[3-4]2.5%65.66342026-03-27

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(7.6%)8.0%42hotter than 42 of 100 peers
Distance from 52-week high(14.7%)(31.4%)74closer to its high than 74 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(6.7%)(1.0%)38pricier than 62 of 100 peers
Book value to price0.090.2825pricier than 75 of 100 peers
Sales to price0.000.313pricier than 97 of 100 peers
Composite equity issuance, five years105.5%20.3%78more equity-funded than 78 of 100 peers
Relative strength against the sector, log excess return(0.29)(0.14)42ahead of 42 of 100 peers

Inputs: market equity $431.9M; EBIT -$34.4M; free cash flow -$29.1M; book equity $38.3M; sales $500,000; cash $5.1M[13].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(70.7%)✗ fail[6,8]
Operating cash flow above zero-$29.1M✗ fail[7]
Return on assets improved(25.6 pts)✗ fail[6,8,11,14]
Operating cash flow exceeds net income$3.7M✓ pass[6-7]
Long-term leverage felln/a[1,8,11]
Current ratio improved353.7 pts✓ pass[9-10,15-16]
No new shares issued25.7%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[8,11]
Cash, filings, liquidity
Cash and equivalents$5.1M[5]
Operating cash flow, four quarters-$31.5M[5,7,17-20]
Months of runway2.0
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing60
10-Q received Aug 10, 2026
Median daily dollar volume$1.2M
63 sessions
Days since newest grade input193

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$61.4M2025-12-312026-03-3010-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax$500,0002018-12-312020-03-2310-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding53,882,5062026-03-272026-03-3010-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding42,855,6602025-03-142025-03-1710-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$5.1M2026-06-302026-08-1010-Qfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$32.8M2025-12-312026-03-3010-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$29.1M2025-12-312026-03-3010-Kfiling · viewer · series
8assetsus-gaap:Assets$46.3M2024-12-312026-03-3010-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$60.6M2025-12-312026-03-3010-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$5.1M2025-12-312026-03-3010-Kfiling · viewer · series
11assetsus-gaap:Assets$54.2M2023-12-312025-03-1710-Kfiling · viewer · series
12assetsus-gaap:Assets$34.4M2022-12-312024-03-1910-Kfiling · viewer · series
13shares outstandingdei:EntityCommonStockSharesOutstanding53,925,6972026-08-032026-08-1010-Qfiling · viewer · series
14net incomeus-gaap:NetIncomeLoss-$24.4M2024-12-312026-03-3010-Kfiling · viewer · series
15current assetsus-gaap:AssetsCurrent$44.6M2024-12-312026-03-3010-Kfiling · viewer · series
16current liabilitiesus-gaap:LiabilitiesCurrent$5.4M2024-12-312026-03-3010-Kfiling · viewer · series
17operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$17.2M2026-06-302026-08-1010-Qfiling · viewer · series
18operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$9.1M2026-03-312026-05-0610-Qfiling · viewer · series
19operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$21.3M2025-09-302025-11-1210-Qfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$14.7M2025-06-302026-08-1010-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.